Everything tagged "pharmaceuticals" across the TickerSpark archives.
Cencora is benefiting from specialty-pharma mix shift, GLP-1 volume, and stronger operating income growth across both U.S. and international segments. The stock looks reasonably valued for a defensive healthcare compounder, though leverage remains a key watch item.
McKesson posted strong Q1 growth, led by oncology and GLP-1 distribution, but the shares already price in much of the upside. The stock earns a Hold as valuation and balance-sheet constraints temper an otherwise solid earnings story.
AstraZeneca earns a Buy as oncology and rare disease offset BioPharmaceuticals pressure. The stock looks reasonably valued with strong cash flow and a clear growth mix shift.
Merck is a Buy as KEYTRUDA still drives growth, WINREVAIR is scaling fast, and the pipeline offers a path through the 2028 patent transition. The stock remains a transition story, but new products and late-stage oncology assets support the case.
Eli Lilly is delivering exceptional growth from Mounjaro and Zepbound, but the stock already reflects a premium multiple and heavy concentration in its obesity franchise.
Bristol-Myers Squibb combines strong cash generation with a broadening growth portfolio, but legacy-product dependence and debt keep the story balanced. The stock looks attractive on valuation, with Eliquis and newer launches helping offset patent pressure.
Johnson & Johnson is a Buy as newer medicines and MedTech growth offset STELARA’s decline. The stock looks fairly valued to slightly attractive with strong cash generation and a broad pipeline.
Novo Nordisk still has a powerful obesity and diabetes franchise, but slower growth, pricing pressure, and tougher competition have shifted the stock into a Hold case. Wegovy momentum and strong profitability support the thesis, while valuation is now close to fair value.
Novartis is navigating Entresto generic pressure with strong growth from Kisqali, Pluvicto, Leqvio, and Kesimpta. The stock looks durable, but valuation and near-term earnings pressure keep the stance at Hold.
Gilead’s HIV franchise is accelerating, with Yeztugo, Trodelvy, and a stronger pipeline offsetting pressure in Veklury and cell therapy. The stock looks attractive for moderate-risk investors with a medium-term horizon.
Sanofi combines strong Dupixent momentum, improving margins, and solid cash generation with a more leveraged balance sheet and a valuation that looks fair rather than cheap. The result is a patient Hold case for medium-term investors.
GSK is leaning on specialty medicines, Shingrix, and a strong HIV franchise to offset declines in legacy categories. The stock looks fairly valued with modest upside, making it more of a steady Hold than a high-conviction buy.
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the GeneratorCancel anytime